{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:56:15Z","timestamp":1790362575160,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-15-00344"],"award-info":[{"award-number":["19-15-00344"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","award":["theme no AAAA-A18-118040390114-8"],"award-info":[{"award-number":["theme no AAAA-A18-118040390114-8"]}],"id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Organophosphorus (OP) compounds represent a serious health hazard worldwide. The dominant mechanism of their action results from covalent inhibition of acetylcholinesterase (AChE). Standard therapy of acute OP poisoning is partially effective. However, prophylactic administration of reversible or pseudo-irreversible AChE inhibitors before OP exposure increases the efficiency of standard therapy. The purpose of the study was to test the duration of the protective effect of a slow-binding reversible AChE inhibitor (C547) in a mouse model against acute exposure to paraoxon (POX). It was shown that the rate of inhibition of AChE by POX in vitro after pre-inhibition with C547 was several times lower than without C547. Ex vivo pre-incubation of mouse diaphragm with C547 significantly prevented the POX-induced muscle weakness. Then it was shown that pre-treatment of mice with C547 at the dose of 0.01\u00a0mg\/kg significantly increased survival after poisoning by 2xLD<jats:sub>50<\/jats:sub>POX. The duration of the pre-treatment was effective up to 96\u00a0h, whereas currently used drug for pre-exposure treatment, pyridostigmine at a dose of 0.15\u00a0mg\/kg was effective less than 24\u00a0h. Thus, long-lasting slow-binding reversible AChE inhibitors can be considered as new potential drugs to increase the duration of pre-exposure treatment of OP poisoning.<\/jats:p>","DOI":"10.1038\/s41598-020-73822-6","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:04:27Z","timestamp":1601978667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Slow-binding reversible inhibitor of acetylcholinesterase with long-lasting action for prophylaxis of organophosphate poisoning"],"prefix":"10.1038","volume":"10","author":[{"given":"Oksana A.","family":"Lenina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Zueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir V.","family":"Zobov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav E.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin A.","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"73822_CR1","unstructured":"Handbook of Toxicology of Chemical Warfare Agents - 3rd Edition. (Academic Press Inc., 2020)."},{"key":"73822_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0140-6736(07)61202-1","volume":"371","author":"M Eddleston","year":"2008","unstructured":"Eddleston, M., Buckley, N. A., Eyer, P. & Dawson, A. H. Management of acute organophosphorus pesticide poisoning. Lancet 371, 597\u2013607 (2008).","journal-title":"Lancet"},{"key":"73822_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/24734306.2017.1373503","volume":"1","author":"PR Chai","year":"2017","unstructured":"Chai, P. R., Boyer, E. W., Al-Nahhas, H. & Erickson, T. B. Toxic chemical weapons of assassination and warfare: nerve agents VX and sarin. Toxicol. Commun. 1, 21\u201323 (2017).","journal-title":"Toxicol. Commun."},{"key":"73822_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11419-017-0376-7","volume":"36","author":"H John","year":"2018","unstructured":"John, H. et al. Fatal sarin poisoning in Syria 2013: forensic verification within an international laboratory network. Forensic Toxicol. 36, 61\u201371 (2018).","journal-title":"Forensic Toxicol."},{"key":"73822_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1164\/rccm.201406-1150CI","volume":"190","author":"EJ Hulse","year":"2014","unstructured":"Hulse, E. J., Davies, J. O. J., Simpson, A. J., Sciuto, A. M. & Eddleston, M. Respiratory complications of organophosphorus nerve agent and insecticide poisoning: Implications for respiratory and critical care. Am. J. Respir. Crit. Care Med. 190, 1342\u20131354 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"73822_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/jat.2760","volume":"33","author":"GA Petroianu","year":"2013","unstructured":"Petroianu, G. A. et al. Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. J. Appl. Toxicol. 33, 894\u2013900 (2013).","journal-title":"J. Appl. Toxicol."},{"key":"73822_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jat.3052","volume":"35","author":"GA Petroianu","year":"2015","unstructured":"Petroianu, G. A., Nurulain, S. M., Hasan, M. Y., Ku\u010da, K. & Lorke, D. E. Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl. J. Appl. Toxicol. 35, 493\u2013499 (2015).","journal-title":"J. Appl. Toxicol."},{"key":"73822_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tox.2006.08.012","volume":"228","author":"A Luci\u0107 Vrdoljak","year":"2006","unstructured":"Luci\u0107 Vrdoljak, A. et al. Pretreatment with pyridinium oximes improves antidotal therapy against tabun poisoning. Toxicology 228, 41\u201350 (2006).","journal-title":"Toxicology"},{"key":"73822_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/jat.3662","volume":"39","author":"DE Lorke","year":"2019","unstructured":"Lorke, D. E. & Petroianu, G. A. Reversible cholinesterase inhibitors as pretreatment for exposure to organophosphates a review. J. Appl. Toxicol. 39, 101\u2013116 (2019).","journal-title":"J. Appl. Toxicol."},{"key":"73822_CR10","doi-asserted-by":"crossref","unstructured":"Lorke, D. E., Nurulain, S. M., Hasan, M. Y., Ku\u010da, K. & Petroianu, G. A. Combined pre- And posttreatment of paraoxon exposure. Molecules25, (2020).","DOI":"10.3390\/molecules25071521"},{"key":"73822_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/jat.1589","volume":"31","author":"DE Lorke","year":"2011","unstructured":"Lorke, D. E. et al. Pretreatment for acute exposure to diisopropylfluorophosphate: in vivo efficacy of various acetylcholinesterase inhibitors. J. Appl. Toxicol. 31, 515\u2013523 (2011).","journal-title":"J. Appl. Toxicol."},{"key":"73822_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-813X(02)00015-3","volume":"23","author":"G Lallement","year":"2002","unstructured":"Lallement, G. et al. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23, 1\u20135 (2002).","journal-title":"Neurotoxicology"},{"key":"73822_CR13","doi-asserted-by":"crossref","unstructured":"Lorke, D. et al. Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: Assessment Using methyl-paraoxon. CNS Neurol. Disord. - Drug Targets 11, 1052\u20131060 (2013).","DOI":"10.2174\/1871527311211080016"},{"key":"73822_CR14","unstructured":"Dunn, M. A., Hackley, B. E. & Sidell, F. R. Pretreatment for nerve agent exposure. In: Sidell, F. R., Takafuji, E. T., Franz, D. R. (Eds). Textb. Mil. Med. Med. Asp. Chem. Biol. Warf. 181\u2013196 (1997)."},{"key":"73822_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.tox.2006.09.012","volume":"233","author":"S Eckert","year":"2007","unstructured":"Eckert, S., Eyer, P. & Worek, F. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 233, 180\u2013186 (2007).","journal-title":"Toxicology"},{"key":"73822_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jnc.14026","volume":"142","author":"P Masson","year":"2017","unstructured":"Masson, P. & Nachon, F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J. Neurochem. 142, 26\u201340 (2017).","journal-title":"J. Neurochem."},{"key":"73822_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1124\/jpet.109.160028","volume":"331","author":"Y Aracava","year":"2009","unstructured":"Aracava, Y., Pereira, E. F. R., Akkerman, M., Adler, M. & Albuquerque, E. X. Effectiveness of donepezil, rivastigmine, and (\u00b1)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J. Pharmacol. Exp. Ther. 331, 1014\u20131024 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"73822_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1006\/taap.2000.8906","volume":"164","author":"E Grauer","year":"2000","unstructured":"Grauer, E., Alkalai, D., Kapon, J., Cohen, G. & Raveh, L. Stress does not enable pyridostigmine to inhibit brain cholinesterase after parenteral administration. Toxicol. Appl. Pharmacol. 164, 301\u2013304 (2000).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"73822_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.neubiorev.2016.10.017","volume":"71","author":"T Myhrer","year":"2016","unstructured":"Myhrer, T. & Aas, P. Pretreatment and prophylaxis against nerve agent poisoning: are undesirable behavioral side effects unavoidable?. Neurosci. Biobehav. Rev. 71, 657\u2013670 (2016).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"73822_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi, L. & Mantegazza, R. Treatment of myasthenia gravis: Focus on pyridostigmine. Clin. Drug Investig. 31, 691\u2013701 (2011).","journal-title":"Clin. Drug Investig."},{"key":"73822_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1289\/ehp.8526","volume":"114","author":"LA McCauley","year":"2006","unstructured":"McCauley, L. A. et al. Studying health outcomes in farmworker populations exposed to pesticides. Environ. Health Perspect. 114, 953\u2013960 (2006).","journal-title":"Environ. Health Perspect."},{"key":"73822_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0896-6273(94)90331-X","volume":"12","author":"L Anglister","year":"1994","unstructured":"Anglister, L., Stiles, J. R. & Salpetert, M. M. Acetylcholinesterase density and turnover number at frog neuromuscular junctions, with modeling of their role in synaptic function. Neuron 12, 783\u2013794 (1994).","journal-title":"Neuron"},{"key":"73822_CR23","doi-asserted-by":"crossref","unstructured":"Petrov, K. et al. C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: Pharmacokinetic and pharmacodynamic studies. Neuropharmacology131, (2018).","DOI":"10.1016\/j.neuropharm.2017.12.034"},{"key":"73822_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrd2082","volume":"5","author":"RA Copeland","year":"2006","unstructured":"Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730\u2013739 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73822_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00018-019-03376-y","volume":"77","author":"F Clarelli","year":"2020","unstructured":"Clarelli, F., Liang, J., Martinecz, A., Heiland, I. & Abel zur Wiesch, P. Multi-scale modeling of drug binding kinetics to predict drug efficacy. Cell. Mol. Life Sci. 77, 381\u2013394 (2020).","journal-title":"Cell. Mol. Life Sci."},{"key":"73822_CR26","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4155\/fmc.11.112","volume":"3","author":"RA Copeland","year":"2011","unstructured":"Copeland, R. A. Conformational adaptation in drug-target interactions and residence time. Future Med. Chem. 3, 1491\u20131501 (2011).","journal-title":"Future Med. Chem."},{"key":"73822_CR27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/17460441.2015.1067196","volume":"10","author":"G Vauquelin","year":"2015","unstructured":"Vauquelin, G. On the \u2019micro\u2019-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action. Expert Opin. Drug Discov. 10, 1085\u20131098 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"73822_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/17460441.2010.512037","volume":"5","author":"G Vauquelin","year":"2010","unstructured":"Vauquelin, G. Rebinding: Or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927\u2013941 (2010).","journal-title":"Expert Opin. Drug Discov."},{"key":"73822_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1039\/C8MD00296G","volume":"9","author":"G Vauquelin","year":"2018","unstructured":"Vauquelin, G. Link between a high kon for drug binding and a fast clinical action: to be or not to be?. Medchemcomm 9, 1426\u20131438 (2018).","journal-title":"Medchemcomm"},{"key":"73822_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bcp.12996","volume":"82","author":"G Vauquelin","year":"2016","unstructured":"Vauquelin, G. Cell membranes\u2026 and how long drugs may exert beneficial pharmacological activity in vivo. Br. J. Clin. Pharmacol. 82, 673\u2013682 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"73822_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1476-5381.2010.00936.x","volume":"161","author":"G Vauquelin","year":"2010","unstructured":"Vauquelin, G. & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488\u2013508 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"73822_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nchembio.1796","volume":"11","author":"GK Walkup","year":"2015","unstructured":"Walkup, G. K. et al. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat. Chem. Biol. 11, 416\u2013423 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"73822_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1021\/acschemneuro.7b00185","volume":"9","author":"PJ Tonge","year":"2018","unstructured":"Tonge, P. J. Drug-Target Kinetics in Drug Discovery. ACS Chem. Neurosci. 9, 29\u201339 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"73822_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108236","author":"SV Lushchekina","year":"2020","unstructured":"Lushchekina, S. V. & Masson, P. Slow-binding inhibitors of acetylcholinesterase of medical interest. Neuropharmacology https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108236 (2020).","journal-title":"Neuropharmacology"},{"key":"73822_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuropharm.2019.05.025","volume":"155","author":"I Zueva","year":"2019","unstructured":"Zueva, I. et al. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer\u2019s disease. Neuropharmacology 155, 131\u2013141 (2019).","journal-title":"Neuropharmacology"},{"key":"73822_CR36","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/cmdc.201500334","volume":"10","author":"VE Semenov","year":"2015","unstructured":"Semenov, V. E. et al. 6-methyluracil derivatives as bifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. ChemMedChem 10, 1863\u20131874 (2015).","journal-title":"ChemMedChem"},{"key":"73822_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1476-5381.2011.01211.x","volume":"163","author":"KA Petrov","year":"2011","unstructured":"Petrov, K. A. et al. Different sensitivities of rat skeletal muscles and brain to novel anti-cholinesterase agents, alkylammonium derivatives of 6-methyluracil (ADEMS). Br. J. Pharmacol. 163, 732\u2013744 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"73822_CR38","doi-asserted-by":"crossref","unstructured":"Petrov, K. et al. Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment. Sci. Rep.8, (2018).","DOI":"10.1038\/s41598-017-18307-9"},{"key":"73822_CR39","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1042\/BCJ20160084","volume":"473","author":"AD Kharlamova","year":"2016","unstructured":"Kharlamova, A. D. et al. Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: Mechanism and possible advantages for myasthenia gravis treatment. Biochem. J. 473, 1225\u20131236 (2016).","journal-title":"Biochem. J."},{"key":"73822_CR40","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1039\/C4MD00225C","volume":"5","author":"VE Semenov","year":"2014","unstructured":"Semenov, V. E. et al. Macrocyclic derivatives of 6-methyluracil as ligands of the peripheral anionic site of acetylcholinesterase. Medchemcomm 5, 1729\u20131735 (2014).","journal-title":"Medchemcomm"},{"key":"73822_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12668-018-0572-x","volume":"9","author":"OA Lenina","year":"2019","unstructured":"Lenina, O. A., Masson, P. & Petrov, K. A. Blockade of metabotropic GABA-B receptors as an approach to reduce toxic peripheral effects of cholinesterase inhibitors. Bionanoscience 9, 38\u201343 (2019).","journal-title":"Bionanoscience"},{"key":"73822_CR42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Ser. B 34, 187\u2013220 (1972).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"73822_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"L Prut","year":"2003","unstructured":"Prut, L. & Belzung, C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463, 3\u201333 (2003).","journal-title":"Eur. J. Pharmacol."},{"key":"73822_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1515\/cclm.1988.26.7.469","volume":"26","author":"T Thomsen","year":"1988","unstructured":"Thomsen, T., Kewitz, H. & Pleul, O. Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors. Clin. Chem. Lab. Med. 26, 469\u2013476 (1988).","journal-title":"Clin. Chem. Lab. Med."},{"key":"73822_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","volume":"148","author":"O Lockridge","year":"2015","unstructured":"Lockridge, O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol. Ther. 148, 34\u201346 (2015).","journal-title":"Pharmacol. Ther."},{"key":"73822_CR46","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1248\/bpb.18.1292","volume":"18","author":"K Yamamoto","year":"1995","unstructured":"Yamamoto, K., Sawada, Y. & Iga, T. Comparative pharmacokinetics of four cholinesterase inhibitors in rats. Biol. Pharm. Bull. 18, 1292\u20131295 (1995).","journal-title":"Biol. Pharm. Bull."},{"key":"73822_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF00636797","volume":"18","author":"SM Aquilonius","year":"1980","unstructured":"Aquilonius, S. M., Eckern\u00e4s, S. \u00c5, Hartvig, P., Lindstr\u00f6m, B. & Osterman, P. O. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18, 423\u2013428 (1980).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"73822_CR48","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s11064-011-0564-5","volume":"36","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. [+]-Huperzine a protects against soman toxicity in guinea pigs. Neurochem. Res. 36, 2381\u20132390 (2011).","journal-title":"Neurochem. Res."},{"key":"73822_CR49","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/0024-3205(94)00501-X","volume":"54","author":"J Grunwald","year":"1994","unstructured":"Grunwald, J., Raveh, L., Doctor, B. P. & Ashani, Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 54, 991\u2013997 (1994).","journal-title":"Life Sci."},{"key":"73822_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","volume":"64","author":"SJ Wood","year":"2001","unstructured":"Wood, S. J. & Slater, R. C. Safety factor at the neuromuscular junction. Prog. Neurobiol. 64, 393\u2013429 (2001).","journal-title":"Prog. Neurobiol."},{"key":"73822_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pneurobio.2015.09.004","volume":"134","author":"CR Slater","year":"2015","unstructured":"Slater, C. R. The functional organization of motor nerve terminals. Prog. Neurobiol. 134, 55\u2013103 (2015).","journal-title":"Prog. Neurobiol."},{"key":"73822_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tox.2005.06.013","volume":"214","author":"H Thiermann","year":"2005","unstructured":"Thiermann, H., Eyer, P., Worek, F. & Szinicz, L. Effects of oximes on muscle force and acetylcholinesterase activity in isolated mouse hemidiaphragms exposed to paraoxon. Toxicology 214, 190\u2013197 (2005).","journal-title":"Toxicology"},{"key":"73822_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1197\/aemj.10.4.295","volume":"10","author":"SB Bird","year":"2003","unstructured":"Bird, S. B., Gaspari, R. J. & Dickson, E. W. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad. Emerg. Med. 10, 295\u2013298 (2003).","journal-title":"Acad. Emerg. Med."},{"key":"73822_CR54","first-page":"225","volume":"7","author":"DL Rickett","year":"1986","unstructured":"Rickett, D. L., Glenn, J. F. & Beers, E. T. Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology 7, 225\u2013236 (1986).","journal-title":"Neurotoxicology"},{"key":"73822_CR55","doi-asserted-by":"crossref","unstructured":"Parvaz, S., Taheri-Ledari, R., Esmaeili, M. S., Rabbani, M. & Maleki, A. A brief survey on the advanced brain drug administration by nanoscale carriers: with a particular focus on AChE reactivators. Life Sci.240, (2020).","DOI":"10.1016\/j.lfs.2019.117099"},{"key":"73822_CR56","doi-asserted-by":"crossref","unstructured":"Pashirova, T. N. et al. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: the acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids Surfaces B Biointerfaces171, (2018).","DOI":"10.1016\/j.colsurfb.2018.07.049"},{"key":"73822_CR57","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1039\/D0NR04037A","volume":"12","author":"EA Burilova","year":"2020","unstructured":"Burilova, E. A. et al. Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer\u2019s disease via an intranasal route. Nanoscale 12, 13757\u201313770 (2020).","journal-title":"Nanoscale"},{"key":"73822_CR58","first-page":"68","volume":"362","author":"VS Reznik","year":"1998","unstructured":"Reznik, V. S. et al. A new class of cholinesterase inhibitors: Tetraalkylammonium derivatives of 6-methyluracil and alloxazine. Dokl. Chem. 362, 68\u201370 (1998).","journal-title":"Dokl. Chem."},{"key":"73822_CR59","doi-asserted-by":"crossref","unstructured":"Ellman, G. L., Courtney, K. D., Andres, V. & Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol.7, (1961).","DOI":"10.1016\/0006-2952(61)90145-9"},{"key":"73822_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2105\/AJPH.38.1_Pt_1.22","volume":"38","author":"ES Weiss","year":"1948","unstructured":"Weiss, E. S. An abridged table of probits for use in the graphic solution of the dosage-effect curve. Am. J. Public Health Nations. Health 38, 22\u201324 (1948).","journal-title":"Am. J. Public Health Nations. Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73822-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:08:47Z","timestamp":1723734527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73822-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73822"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73822-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16611"}}